FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381716537> ?p ?o ?g. }

• W4381716537 endingPage "888" @default.
• W4381716537 startingPage "877" @default.
• W4381716537 abstract "Obesity is a major risk factor for many leading causes of illness and death worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults with obesity. Download a PDF of the Research Summary. In this phase 2, randomized, double-blind trial, we enrolled adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes. Participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks. The percentage change from baseline in body weight was assessed at week 26 (primary end point) and at week 36 (secondary end point). A total of 272 participants underwent randomization. At baseline, the mean body weight was 108.7 kg, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 37.9. At week 26, the mean change from baseline in body weight ranged from −8.6% to −12.6% across the orforglipron dose cohorts and was −2.0% in the placebo group. At week 36, the mean change ranged from −9.4% to −14.7% with orforglipron and was −2.3% with placebo. A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants who received orforglipron, as compared with 9% who received placebo. The use of orforglipron led to improvement in all prespecified weight-related and cardiometabolic measures. The most common adverse events reported with orforglipron were gastrointestinal events, which were mild to moderate, occurred primarily during dose escalation, and led to discontinuation of orforglipron in 10 to 17% of participants across dose cohorts. The safety profile of orforglipron was consistent with that of the GLP-1 receptor agonist class. Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists. (Funded by Eli Lilly; GZGI ClinicalTrials.gov number, NCT05051579.) QUICK TAKE VIDEO SUMMARYAn Oral GLP-1 Receptor Agonist for Adults with Obesity 02:15" @default.
• W4381716537 created "2023-06-24" @default.
• W4381716537 creator A5004471830 @default.
• W4381716537 creator A5013944614 @default.
• W4381716537 creator A5017710279 @default.
• W4381716537 creator A5027441223 @default.
• W4381716537 creator A5040811419 @default.
• W4381716537 creator A5045489578 @default.
• W4381716537 creator A5055547863 @default.
• W4381716537 creator A5057140892 @default.
• W4381716537 creator A5072643825 @default.
• W4381716537 creator A5077985126 @default.
• W4381716537 creator A5081732583 @default.
• W4381716537 creator A5085855526 @default.
• W4381716537 creator A5090850437 @default.
• W4381716537 date "2023-09-07" @default.
• W4381716537 modified "2023-10-16" @default.
• W4381716537 title "Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity" @default.
• W4381716537 cites W2394582105 @default.
• W4381716537 cites W2425644022 @default.
• W4381716537 cites W2951522032 @default.
• W4381716537 cites W3045729180 @default.
• W4381716537 cites W3093042356 @default.
• W4381716537 cites W3099724881 @default.
• W4381716537 cites W3127371223 @default.
• W4381716537 cites W3166038843 @default.
• W4381716537 cites W3176790398 @default.
• W4381716537 cites W3177122952 @default.
• W4381716537 cites W3177393241 @default.
• W4381716537 cites W3191712049 @default.
• W4381716537 cites W3205201678 @default.
• W4381716537 cites W4210940103 @default.
• W4381716537 cites W4281627591 @default.
• W4381716537 cites W4281934192 @default.
• W4381716537 cites W4377220176 @default.
• W4381716537 cites W807162506 @default.
• W4381716537 cites W917052595 @default.
• W4381716537 doi "https://doi.org/10.1056/nejmoa2302392" @default.
• W4381716537 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37351564" @default.
• W4381716537 hasPublicationYear "2023" @default.
• W4381716537 type Work @default.
• W4381716537 citedByCount "16" @default.
• W4381716537 countsByYear W43817165372023 @default.
• W4381716537 crossrefType "journal-article" @default.
• W4381716537 hasAuthorship W4381716537A5004471830 @default.
• W4381716537 hasAuthorship W4381716537A5013944614 @default.
• W4381716537 hasAuthorship W4381716537A5017710279 @default.
• W4381716537 hasAuthorship W4381716537A5027441223 @default.
• W4381716537 hasAuthorship W4381716537A5040811419 @default.
• W4381716537 hasAuthorship W4381716537A5045489578 @default.
• W4381716537 hasAuthorship W4381716537A5055547863 @default.
• W4381716537 hasAuthorship W4381716537A5057140892 @default.
• W4381716537 hasAuthorship W4381716537A5072643825 @default.
• W4381716537 hasAuthorship W4381716537A5077985126 @default.
• W4381716537 hasAuthorship W4381716537A5081732583 @default.
• W4381716537 hasAuthorship W4381716537A5085855526 @default.
• W4381716537 hasAuthorship W4381716537A5090850437 @default.
• W4381716537 hasConcept C126322002 @default.
• W4381716537 hasConcept C142724271 @default.
• W4381716537 hasConcept C168563851 @default.
• W4381716537 hasConcept C203092338 @default.
• W4381716537 hasConcept C204243189 @default.
• W4381716537 hasConcept C204787440 @default.
• W4381716537 hasConcept C27081682 @default.
• W4381716537 hasConcept C2780221984 @default.
• W4381716537 hasConcept C2780586474 @default.
• W4381716537 hasConcept C3017894415 @default.
• W4381716537 hasConcept C511355011 @default.
• W4381716537 hasConcept C544821477 @default.
• W4381716537 hasConcept C71924100 @default.
• W4381716537 hasConceptScore W4381716537C126322002 @default.
• W4381716537 hasConceptScore W4381716537C142724271 @default.
• W4381716537 hasConceptScore W4381716537C168563851 @default.
• W4381716537 hasConceptScore W4381716537C203092338 @default.
• W4381716537 hasConceptScore W4381716537C204243189 @default.
• W4381716537 hasConceptScore W4381716537C204787440 @default.
• W4381716537 hasConceptScore W4381716537C27081682 @default.
• W4381716537 hasConceptScore W4381716537C2780221984 @default.
• W4381716537 hasConceptScore W4381716537C2780586474 @default.
• W4381716537 hasConceptScore W4381716537C3017894415 @default.
• W4381716537 hasConceptScore W4381716537C511355011 @default.
• W4381716537 hasConceptScore W4381716537C544821477 @default.
• W4381716537 hasConceptScore W4381716537C71924100 @default.
• W4381716537 hasFunder F4320307758 @default.
• W4381716537 hasIssue "10" @default.
• W4381716537 hasLocation W43817165371 @default.
• W4381716537 hasLocation W43817165372 @default.
• W4381716537 hasOpenAccess W4381716537 @default.
• W4381716537 hasPrimaryLocation W43817165371 @default.
• W4381716537 hasRelatedWork W1866091461 @default.
• W4381716537 hasRelatedWork W2000335303 @default.
• W4381716537 hasRelatedWork W2047277250 @default.
• W4381716537 hasRelatedWork W2069654038 @default.
• W4381716537 hasRelatedWork W2363570094 @default.
• W4381716537 hasRelatedWork W2403825624 @default.
• W4381716537 hasRelatedWork W2625095604 @default.
• W4381716537 hasRelatedWork W2777447650 @default.
• W4381716537 hasRelatedWork W4380150467 @default.

• next